Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial (EDI‐PIO) in chronic myeloid leukemia with deep molecular response
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Hematology"
DOI: 10.1002/ajh.25986
Abstract: with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190-2196. 3. Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med. 2011;364(8):775-776.… read more here.
Keywords: lymphoma; phase; gambacorti passerini; alk positive ... See more keywords
Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2420
Abstract: Crizotinib has demonstrated good efficacy in patients with anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC). Continuing crizotinib therapy beyond progressive disease (CBPD) can achieve ongoing survival benefit in real‐world clinical practice. In terms… read more here.
Keywords: therapy; alk positive; efficacy; non small ... See more keywords
Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer treatment and research"
DOI: 10.1007/978-3-319-99716-2_6
Abstract: Anaplastic Large Cell Lymphomas (ALCL) are clinically aggressive and pathologically distinct lymphoid neoplasms that originate from a mature post-thymic T-cell. The contemporary World Health Organization (WHO) Classification of Haematologic Malignancies recognizes two distinct subtypes of… read more here.
Keywords: alcl; alk positive; management; large cell ... See more keywords
Life-threatening paraneoplastic cardiovascular events in ALK-positive anaplastic large cell lymphoma
Sign Up to like & getrecommendations! Published in 2021 at "Annals of Hematology"
DOI: 10.1007/s00277-021-04679-6
Abstract: Paraneoplastic hypercholesterolemia has almost exclusively been reported in patients with hepatocellular carcinoma [1] and only in one case of gastric hepatoid adenocarcinoma [2] and one case of renal adenocarcinoma [3] (Table 1). Here, we report… read more here.
Keywords: positive anaplastic; alk positive; large cell; cardiovascular events ... See more keywords
Localized ALK-positive histiocytosis in a Chinese woman: report of a case in the lung with a novel EML4-ALK rearrangement
Sign Up to like & getrecommendations! Published in 2021 at "Virchows Archiv"
DOI: 10.1007/s00428-021-03092-8
Abstract: ALK-positive histiocytosis (APH) is a newly defined entity with specific histological features and a highly recurrent KIF5B-ALK gene fusion. APH is characterized by clonal proliferation of histiocytes and can present as either systemic or localized.… read more here.
Keywords: alk; alk rearrangement; alk positive; positive histiocytosis ... See more keywords
Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-020-03476-4
Abstract: Crizotinib is the first-line small molecule tyrosine kinase inhibitor for ALK-positive non-small cell lung cancer. In this study, a retrospective pharmacogenomics investigation was conducted to explore the relationship between genes related to RTK downstream signaling… read more here.
Keywords: crizotinib; alk positive; toxicity; crizotinib induced ... See more keywords
The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-021-03546-1
Abstract: Anaplastic lymphoma kinase (ALK) gene rearrangement exists in approximately 3–7% of non-small cell lung cancer (NSCLC) and more than 15% split or isolated red signals among 50 tumor nuclei scored in the FISH analysis defines… read more here.
Keywords: alk; alk rearrangement; break apart; alk positive ... See more keywords
Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-021-01015-z
Abstract: Lorlatinib demonstrated efficacy (including intracranial activity) in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in a phase I/II study (NCT01970865). This analysis describes the pharmacokinetics (PK) of lorlatinib following single and… read more here.
Keywords: phase; single multiple; alk positive; multiple dosing ... See more keywords
Alectinib: A Review in Advanced, ALK-Positive NSCLC
Sign Up to like & getrecommendations! Published in 2018 at "Drugs"
DOI: 10.1007/s40265-018-0952-0
Abstract: Alectinib (Alecensa®) is a potent and highly selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor. Oral alectinib monotherapy is approved in the EU as first-line treatment for adults with advanced ALK-positive non-small cell lung cancer… read more here.
Keywords: positive nsclc; nsclc; advanced alk; treatment ... See more keywords
Brigatinib in Patients With Alectinib‐Refractory ALK‐Positive NSCLC
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2018.06.005
Abstract: Introduction: The second‐generation anaplastic lymphoma kinase (ALK) inhibitor alectinib recently showed superior efficacy compared to the first‐generation ALK inhibitor crizotinib in advanced ALK‐rearranged NSCLC, establishing alectinib as the new standard first‐line therapy. Brigatinib, another second‐generation… read more here.
Keywords: positive nsclc; alectinib refractory; alk; alk positive ... See more keywords
Optimal management of ALK-positive NSCLC progressing on crizotinib.
Sign Up to like & getrecommendations! Published in 2017 at "Lung cancer"
DOI: 10.1016/j.lungcan.2017.02.003
Abstract: Crizotinib is an anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor (-TKI) that represents the standard first-line treatment of patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer (NSCLC). In this setting, crizotinib has demonstrated a response… read more here.
Keywords: nsclc; alk; alk tki; crizotinib ... See more keywords